RxDoctor Payments Data

Veronica Guettler

Psychiatric/Mental Health · Chipley, FLNPI 1487086682

Payments from drug & device makers

$2,123in general payments, 2019–2025

Across 95 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$664
  • Alkermes, Inc.$348
  • Otsuka America Pharmaceutical, Inc.$190
  • Axsome Therapeutics, Inc.$163
  • Vanda Pharmaceuticals Inc.$147
  • Tris Pharma Inc$122
  • plus $489 from 9 others

What the payments were for

  • Food & beverage$2,09699%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,123 in reported general payments places this provider in the 70th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$5,701
Medicare patients
42
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LybalviOlanzapine/Samidorphan Malate25$38,867
VraylarCariprazine Hcl22$31,065
Lurasidone Hcl32$26,729
AuvelityDextromethorphan Hbr/Bupropion14$17,603
TrintellixVortioxetine Hydrobromide11$8,347
VyvanseLisdexamfetamine Dimesylate11$4,016
Ziprasidone Hcl16$1,878
Desvenlafaxine Succinate ErDesvenlafaxine Succinate17$1,384
Aripiprazole57$1,201
Quetiapine Fumarate71$1,158
Trazodone Hcl112$1,117
Hydroxyzine Hcl28$1,051
Clonazepam131$1,045
Buspirone Hcl57$924
Quetiapine Fumarate ErQuetiapine Fumarate18$911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Lybalvi$348$38,86725 claims
AbbVieVraylar$664$31,06522 claims
Axsome Therapeutics, Inc.Auvelity$163$17,60314 claims
Almatica Pharma LLCSertraline Hcl$25$23739 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Chipley

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →